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Abstract  
BACKGROUND: Parapneumonic effusions complicating pneumonia are associated with increased 
morbidity and mortality.  
AIM: To determine the role of the clinical, laboratory and radiographic features to the differential 
diagnosis of patients with community- acquired pneumonia (CAP) without effusion, uncomplicated 
parapneumonic effusion (UCPPE) and complicated parapneumonic effusion (CPPE). 
MATERIAL AND METHODS: We analysed 148 patients with CAP without effusion, 50 with UCPPE 
and 44 with CPPE. In three groups of patients, the majority was male patients (58.11%, 58%, 
61.36%) consequently.  
RESULTS: The chronic heart failure was the most common comorbidity in a group with CAP (28; 
18.92%) and UCPPE (7; 14%), alcoholism (12;12.77%) in a group with CPPE. Patients with CPPE 
had significantly longer fever compared to patients with CAP without effusion (p = 0.003). Pleuritic 
chest pain (86.36%) and dyspnea (88.64%) were the most common symptoms in CPPE, then to 
group with UCPPE (60%; 52%), and in CAP without effusion (25.68%; 47,97%). Diffuse pulmonary 
changes were detected more frequently in the group with CAP without effusion compared with the 
group with CPPE (64.86 % vs. 27.27 %), while the segment lung changes were more common in 
patients with CPPE (50% vs. 20.27%). Patients with CPPE were significant with higher erythrocytes 
sedimentation rate (ESR), white blood cells (WBC) and serum C- reactive protein (CRP) than it the 
other two groups (p = 0.00090, p = 0.01, p= 0.000065).  
CONCLUSION: Proper analysis of clinical, laboratory and radiographic features of patients with 
CAP and parapneumonic effusion can prevent mismanagement in these patients and will reduce 
morbidity and mortality. 
 
 
Introduction 
 
Pleural effusion represents a common 
complication of community- acquired pneumonia. 
Parapneumonic effusions occur in 20- 40% of patients 
who are hospitalised with pneumonia [1]. The 
mortality rate in patients with parapneumonic 
effusions is higher than that in patients with 
pneumonia without parapneumonic effusion [1]. Some 
of the excess mortality is due to the mismanagement 
of pneumonia and parapneumonic effusion [1, 2]. The 
clinical classification of parapneumonic effusions 
identifies three groups with a distinct prognosis [1-3]. 
First, there is the simple or uncomplicated 
parapneumonic effusion (UCPPE), which should 
resolve with appropriate antibiotic therapy without any 
consequences within the pleural space. Second, there 
is a complicated parapneumonic effusion (CPPE) 
denoting the presence of bacterial infection in the 
pleural space with an associated inflammatory 
response. A complicated effusion sometimes requires 
pleural drainage to resolve and without treatment may 
progress to an empyema [1-4]. CPPE occurs in 10% 
of all patients hospitalised with effusion [4].  
Finally, empyema represents frank pus in the 
pleural space requires pleural drainage and may also 
require surgical treatment [3-5]. About 60% of 
empyemas are related to a primary pneumonic 
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process; therefore risk factors for pleural infection are 
similar to those for pneumonia [1, 6]. Independent risk 
factors for the development of empyema include 
diabetes, alcohol and intravenous abuse, 
immunosuppression, gastro- oesophagal reflux 
disease, aspiration and poor oral hygiene [4, 7, 8]. 
After a variable time interval, pleural infection enters 
an organizing
,
 stage characterised by fibroblast 
proliferation and the development of solid fibrous peel. 
This inhibits lung reexpansion and usually 
necessitates surgical thoracotomy and decortication 
[7, 8].  
There is considerable variation in the course 
and aggressiveness of parapneumonic effusions; 
therefore an understanding of its progression is 
important [4]. Along out with increased mortality, 
complicated parapneumonic effusion and empyema 
often necessitate prolonged treatment, longer hospital 
stay and interventions. Thus, identification of these 
patients and prompt management is critical.  
Recent studies have shown that relying on 
clinical findings alone do not predict the clinical course 
of illness in individual patients [9-11]. The dilemma of 
differentiating between this three diagnosis, using 
history, physical examination, radiographic findings 
and markers of inflammation, is challenging [9-11].  
In this study, we want to see the possibility of 
using standard examinations that are available in daily 
practice to prevent possible complications and to 
understand the relationship of parapneumonic 
effusion with pneumonia. 
 
 
Material and Methods 
 
Of 1059 patients with CAP, 304 patients were 
excluded from the study according to the criteria for 
exclusion, and because it had realised ultrasound of 
the pleura and lung as a more sensitive method for 
the diagnosis of parapneumonic effusion of lung X-
ray. Excluding criteria were: cancer and malignant 
effusion, hospital- acquired pneumonia, solid organ 
transplanting, transudate effusion, vasculitis, 
pulmonary emboli (PE), pulmonary tuberculosis and 
age less than 18 years. From 755 patients, 175 
(23.18%), had parapneumonic effusion. Thoracentesis 
was performed in 94 (53.71%) patients, 50 patients 
wеre with uncomplicated parapneumonic effusions 
(UCPPE) and 44 with complicated parapneumonic 
effusions (CPPE). Of 580 patients with CAP without 
effusion, we analysed 148 patients with CAP without 
effusion because other patients did not have all the 
necessary laboratory and radiographic parameters to 
be analysed in this study. The patients were 
diagnosed and treated in University Infectious 
Diseases Clinic, Faculty of Medicine, Skopje in the 
Department of Respiratory Diseases in the period 
from September 2011 to June 2015.  
The demographic characteristics, physical 
examination findings, laboratory and microbiological 
findings of all study participants were monitored 
regularly on University Infectious Diseases Clinic. 
Initial lung X- rays were taken for all patients at the 
Institute of Radiology, Medical Faculty in Skopje. After 
admission, all the patients underwent an ultrasound of 
the pleura and lung with a three- dimensional echo at 
the University Infectious Diseases Clinic for diagnosis 
of pleural effusions and implementation of diagnostic 
thoracocentesis if the size of effusion was more than 
10 mm. After verification of pneumonia and pleural 
effusion, the distinction between transudation and 
exudates was done according to Light
’
s criteria. 
Exudative pleural effusion is one that meets at least 
one of the criteria of Light. The transudate if the 
effusion that meets all three criteria at the same time: 
1) to have intercourse protein p/s below 0.5; 2) 
intercourse LDH p/s below 0.6, and 3) LDH in the 
pleural fluid under 282 U/L, which is the lowest limit in 
our laboratory. Than exudative pleural effusion 
according to their evolution and on the basis of pH, 
glucose and LDH value in the pleural fluid are division: 
- Uncomplicated parapneumonic effusions: pH > 7.2, 
glucose >60 mg/dl, LDH< 1000UI/ml; - Complicated 
parapneumonic effusions: pH<7.2, glucose <60 mg/dl, 
LDH>/= 1000 UI/ml.  
ERS was determined in all three groups of 
patients at admission on a clinic. ERS measures the 
distance through which erythrocytes fall within 1 hour 
in a vertical tube of anticoagulated blood, and is 
measured in millimetres/hour. The blood is drawn into 
a vertical tube anticoagulated with sodium citrate. 
Leukocyte count (WBC) was also determined in the 
clinic laboratory by the white blood cell counter 
(number per microliter).The amount of protein is 
determined in the same biochemical laboratory with 
the standard method. C- reactive protein (CRP) was 
measured by quantitative methods in biochemistry 
laboratory of the same clinic with quantitative 
sandwich enzyme heterogeneous test, Ektahem 
Clinical Chemistry test, an automated biochemical 
analyser Vitros 250.  
  
Statistical analysis  
Statistical analysis was conducted using 
SPSS 17 for Windows. The testing of normality in the 
distribution of the data was used Kolmogorov-Smirnov 
and Shapiro-Wilk's W tests. Categorical traits of 
displayed by absolute and relative representation with 
quantitative traits mean SD, median, minimum, 
maximum, 25-75 percentiles. To compare three 
groups of subjects in relation to the variables analysed 
were used Kruskal-Wallis ANOVA and Mann-Whitney 
U тест (Z). The level of significance or importance 
was taken the value of p < 0.05, a significantly higher 
value of p < 0.01.  
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Results 
 
In three groups of patients, majority was male 
patients (58.11%, 58%, and 61.36% consequently). It 
was insignificant the difference in the distribution of 
patients with CAP without effusion, UCPPE and CPPE 
in terms of their sex (p = 0.9). The average age of 
patients only with CAP was 54.58 ± 17.5 years, in 
UCPPE 55.5 ± 16.6 and in a group with CPPE was 
51.91 ± 18.4 and there was no statistical difference (p 
= 0.58) (Table 1). 
Table 1: Demographic characteristics of three groups of 
patients 
Variable CAP 
N = 148 
UCPPE 
N = 50 
CPPE 
N = 44 
p value 
Sex n (%)     
Male 86 (58.11) 29 (58) 27 (61.36) 
а
p = 0.9 
Female 62 (41.89) 21 (42) 17 (38.64) 
Age (years) mean ± SD, min-max 
 54.58 ± 17.5 
18-89 
55.5 ± 16.6 
21-83 
51.91 ± 18.4 
18-93 
b
p = 0.58 
а
p (Chi-square test); 
b
p (Analysis of variance). 
 
Analysis of the results regarding the presence 
of comorbidity showed a significant difference 
between the three groups of subjects (p = 0.028). 
Usually with accompanying diseases were CPPE 
patients (77%), compared with patients with UCPPE 
(56%) and CAP without effusion (52.7%). 
The chronic heart failure was the most 
common comorbidity in a group with CAP (28; 
18.92%) and UCPPE(7; 14%), alcoholism 
(12;12.77%) in a group with CPPE. The structure of 
morbidity among the three groups of respondents is 
presented in Table 2. 
Table 2: Comorbidity of the three patient groups 
Type of comorbidity n (%) CAP without 
effusion 
N= 78 (52.7%) 
UCPPE 
N=28 (56%) 
CPPE 
N=34 (77%) 
COPD 8 (5.41) 2 (4) 2 (4.55) 
Chronic heart failure 28 (18.92) 7 (14) 2 (4.55) 
Diabetes melitus 13 (8.78) 7 (14) 3 (6.82) 
Chronic liver disease 2 (1.35) 1 (2) 1 (2.27) 
Renal failure 2 (1.35) 1 (2) 0 
Alcoholism 4 (2.7) 1 (2) 11 (25) 
Malignancy 3 (2.03) 4 (8) 2 (4.55) 
Chronic systemic disease 3 (2.03) 1 (2) 2 (4.55) 
Poor dental hygiene 0 0 2 (4.55) 
Drug users 0 0 2 (4.55) 
Neurological disease 3 (2.03) 0 2 (4.55) 
Haematological disease 2 (1.35) 0 0 
Two or three comorbidities 35 (23.65) 3 (6) 5 (11.36) 
Other diseases 7 (4.73) 1 (2) 0 
 
The three groups of participants significantly 
differ in terms of frequency of occurrence of dyspnea 
(p = 0.000009). Very high percentage of patients with 
CPPE had dyspnea (88.64 %), despite the 
significantly lower percentage of patients with CAP 
without effusion (47.97%), and significantly lower 
percent patients with UCPPE (52%). Pleuritic chest 
pain (86.36%) was the most common symptom and 
significantly more often in a group with CPPE, then to 
group with UCPPE (60%), and group with CAP 
without effusion (25.68%) (Table 3).  
Table 3: Clinical characteristics of the three groups of patients 
Variable CAP without 
effusion 
N = 148 
N (%) 
UCPPE 
N = 50 
N (%) 
CPPE 
N = 44 
N (%) 
p-value 
 1 2 3 
 
Fever 107 (72.3) 30 (60) 29 (65.91) 
a
p = 0.2 
Catarrhal symptoms 51 (34.46) 16 (32) 11 (25) 
a
p = 0.5 
Sore throat 61 (41.22) 15 (30) 10 (22.73) 
a
p = 0.05 
Hyperemia of the 
tonsils and pharynx 
78 (52.7) 21 (42) 19 (43.18) 
a
p = 0.3 
Cough type 
Productive 43 (29.05) 12 (24) 20 (45.45) 
a
p = 0.049* 
2vs3 p = 0.005** Serous sputum 29 (19.59) 15 (30) 3 (6.82) 
Haemoptisis 14 (9.46) 2 (4) 6 (13.64) 
Dry cough 40 (27.03) 15 (30) 7 (15.91) 
Without cough 22 (14.86) 6 (12) 8 (18.18) 
Headache  95 (64.19) 33 (66) 23 (52.27) 
a
p = 0.3 
Malaise  138 (93.24) 45 (90) 44 (100) 2vs3 
a
p = 0.038* 
Myalgia  81 (54.73) 23 (46) 24 (54.55) 
a
p = 0.5 
Arthralgia  66 (44.59) 19 (38) 17 (38.64) 
a
p = 0.6 
Weight loss  76 (51.35) 30 (60) 38 (86.36) 
a
p = 0.0002** 
1vs3 p = 
0.00003** 
2vs3 p = 0.004** 
Dispnea 71 (47.97) 26 (52) 39 (88.64) 
a
p = 0.000009** 
1vs3 p = 
0.00002** 
2vs3 p = 0.0001** 
Days of disease before hospitalisation 
1 – 4 days 62 (41.89) 23 (46) 9 (20.45) 
a
p < 0.001 
1vs3 p = 0.00006 
1vs3 p = 0.001** 
2vs3 p = 0.017* 
5 – 10 days 70 (47.3) 20 (40) 21 (47.73) 
 > 10 days 16 (10.81) 7 (14) 14 (31.82) 
Days of disease before hospitalisation (mean ± SD) median (25-75
th
quartiles) 
 6.39 ± 6.0 6.24 ± 4.7 10.59 ± 8.8 
c
p = 0.0002** 
1vs3 p = 
0.00006** 
 5 (3-7) 4 (3-7) 10 (5-13.5) 
Length of hospitalisation (mean±SD) median (25-75
th
quartiles) 
 12.39 ± 2.7 15.78 ± 4.3 20.75 ± 18 
c
p < 0.0001 
1vs2 p < 0.0001 
1vs3 p < 0.0001 
 12 (10-14) 15 (13-16) 21(18-23) 
a
p
 
(Chi-square test); 
c
p (Kruskal-Wallis test); *p < 0.05; **p < 0.01. 
 
Participants from all three groups had a 
significantly different duration of disease symptoms 
before hospitalisation (p = 0.0002). This difference 
was due to a significantly longer duration of symptoms 
in the group with CPPE compared with the group wit 
CAP without effusion (p = 0.00006). 
 The length of hospitalisation significantly 
differed among the three groups of patients (p < 
0.0001). The average time of hospital days shows that 
half of the patients with CPPE were in the hospital 
more than 21 days, half of the patients with CAP 
without effusion were hospitalised more than 12 days, 
50% of patients with UCPPE more than 15 days. The 
results are shown in Table 3. 
The values of body temperature before 
hospitalisation insignificant differed between patients 
of the three groups (p = 0.07). Again along the 
duration of fever before hospitalisation was significant 
among the three groups of subjects (p = 0.0006). 
In patients with CPPE average period of the 
fever duration during hospitalisation is 4 days, in a 
group with CAP without effusion is 2 days, and in 
patients with UCPPE is 3 days. Average value of 
temperature during hospital treatment in patients with 
CPPE was 39
0
C (38.25-39.8
0
C), in patients with 
UCPPE was 38.4
0
C (37.5-39.6
0
C) and the lowest 
values were noted in the patient with CAP without 
effusion 38.3
0
C (37.4-39.2
0
C) (Table 4). 
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Table 4: Value and duration of temperature in the three patients 
groups 
Variable CAP without 
effusion 
N = 148 
UCPPE 
N = 50 
CPPE 
N = 44 
p-value 
 1 2 3  
Values of temperatures before hospitalisation, °C [n (%)] 
< 37.1°C 8 (5.41) 0 0  
37.1 – 37.7°C 7 (4.73) 9 (18) 1 (2.27) 
37.8 – 39°C 70 (47.3) 24 (48) 24 (54.55) 
39.1 – 40°C 39 (26.35) 14 (28) 4 (9.09) 
40°C > 24 (16.22) 3 (6) 15 (34.09) 
Values of temperatures before hospitalisation, (mean ± SD) median (25-75
th
quartiles) 
 38.81 ± 3.1 38.87 ± 0.9 39.37 ± 1.0 
c
p = 0.07 
 39 (38.5-40) 39 (38.3-39.8) 39 (38.5-40.5) 
Duration of temperatures before hospitalisation (days) (mean ± SD) median (25-
75
th
quartiles) 
 4.36 ± 4.2 4.0 ± 2.9 7.45 ± 6.4 
c
p = 0.0006** 
1вс3 p = 0.0003** 
2вс3 p = 0.001* 
 4 (2-5.5) 3.5 (3-5) 6 (3-10) 
Duration of temperatures during hospitalisation, °C (days) [n (%)] 
Without fever  92 (62.16) 18 (36) 20 (45.45)  
1 – 2 days 22 (14.86) 18 (36) 6 (13.64) 
3 – 4 days 13 (8.78) 11 (22) 13 (29.55) 
5 – 7 days 9 (6.08) 0 5 (11.36) 
 > 7 days 12 (8.11) 3 (6) 0 
Duration of temperatures during hospitalisation (days) mean ± SD median (25-
75
th
quartiles) 
 2.7 ± 3.1 3.3 ± 2.0 4.77 ± 5.0 
c
p = 0.0005** 
1вс3 p = 0.003**  2 (1-3) 3 (2-4) 4 (1.5-5) 
Values of temperatures during hospitalisation, °C [n (%)] 
< 37.1°C 23 (15.54) 6 (12) 1 (2.27)  
37.1 – 37.7°C 27 (18.24) 9 (18) 7 (15.91) 
37.8 – 39°C 53 (35.81) 17 (34) 15 (34.09) 
39.1 – 40°C 41 (27.7) 17 (34) 17 (38.64) 
40°C > 4 (2.7) 1 (2) 4 (9.09) 
Values of temperatures during hospitalisation mean ± SD median (25-75
th
quartiles) 
 38.38 ± 1.1 38.55 ± 1.1 38.9 ± 1.1 
c
p = 0.02* 
1вс3 p = 0.006**  38.3 (37.4-39.2) 38.4 (37.5-39.6) 39(38.25-39.8) 
c
p (Kruskal-Wallis test); *p < 0.05; **p < 0.01. 
 
In the admission to the clinic, patients with 
CAP without effusion, with UCPPE and CPPE were 
significantly different ERS rate (p = 0.00090). Patients 
with CPPE had average ERS in the first hour of 74.77 
± 27.3 mm/h and is significantly higher than the 
average value in the group with pneumonia without 
effusion (56.35 ± 28.6), and the average value of the 
group with UCPPE (60.02 ± 27.7). In the admission, 
WBC was significantly higher in the group with CPPE 
versus the group with CAP without effusion (median 
12.6 vs. 10.6, p = 0.01). Normal values of WBC had 
more patients with CAP without effusion (21.62 % vs. 
34.09 %), while the values of WBC higher than 
20x10
9
/L had more patients with CPPE (25% vs. 
10.14%). The values of the inflammatory marker CRP 
at the admission and discharge on the clinic 
significantly dependent on the form of manifestation of 
community-acquired pneumonia (CAP) or its 
manifestation without effusion, with UCPPE or CPPE 
(p < 0.0001 and p = 0.04 respectively). The mean 
values of CRP (231.79 ± 112.2 mg/L) were 
significantly higher in the group with CPPE compared 
with the group wit CAP without effusion (139.48 ± 
105.7 mg/L) (p = 0.000004), and compared with the 
group with UCPPE (163.8 ± 147.9 mg/L) (p = 
0.000065) (Table 5). 
Radiographic findings regarding the type of 
infiltration were significantly different between patients 
with CAP without effusion and CPPE (p = 0.00019), 
and between the two patient groups with effusion (p = 
0.035). Alveolar infiltrates often had as radiographic 
finding patients with CPPE (65.91 %). Interstitial 
infiltration was the most common radiographic finding 
in the group with CAP without effusion (14.86 %), this 
finding was no patient with CPPE, and the mixed 
finding was most common in the group with CAP 
without effusion (51.35%). 
Table 5: Markers of inflammation in the three clinical groups of 
patients 
Variable  CAP 
N = 148 
UCPPE 
N = 50 
CPPE 
N = 44 
p value 
 1 2 3  
ERS mm/h - admission n (%) 
 ≤ 20 20 (13.51) 4 (8) 2 (4.55)  
21 – 40  36 (24.32) 8 (16) 6 (13.64) 
41 – 60  37 (25) 19 (38) 8 (18.18) 
61 – 100  52 (35.14) 17 (34) 24 (54.55) 
 > 100 3 (2.03) 2 (4) 4 (9.09) 
ERS mm/h mean ± SD median (25-75
th
quartiles) 
Admission 56.35 ± 28.6 60.02 ± 27.7 74.77 ± 27.3 
b
p = 0.0009** 
1вс3 p = 0.0004** 
2вс3 p = 0.03* 
c
p = 0.3 
 60 (33.5-80) 55 (45-80) 76.5 (60-97) 
Dischagre 34.8 ± 24.0 36.12 ± 22.2 41.73 ± 26.8 
 31 (11-50) 40 (15-52) 40 (20-60) 
WBC x 10
9
/L n (%) 
 ≤ 4 13 (8.78) 3 (6) 0  
 4 – 9 48 (32.43) 15 (30) 7 (15.91) 
 9.1 – 12 32 (21.62) 14 (28) 15 (34.09) 
12.1 – 15 26 (17.57) 3 (6) 6 (13.64) 
15.1 – 20 14 (9.46) 10 (20) 5 (11.36) 
 > 20 15 (10.14) 5 (10) 11 (25) 
WBC x 10
9
/L mean ± SD median (25-75
th
quartiles) 
Admission 11.56 ± 6.8 12.19 ± 6.0 14.68 ± 6.6 
c
p = 0.013* 
1вс3 
d
p = 0.01* 
b
p = 0.26 
 10.6 (6.4-14.1) 11.1 (8.1-16.7) 12.6 (10.2-20.2) 
Dischagre 7.91 ± 2.6 7.26 ± 1.9 7.62 ± 2.8 
 7.6 (6.2-9.3) 7.5 (5.8-8.6) 6.8 (6-8.8) 
CRP serum means ± SD median (25-75
th
quartiles) 
 Admission 139.48 ± 105.7 163.8 ± 147.9 231.79± 112.2 
c
p < 0.0001 
1вс3 
d
p = 
0.000004** 
2вс3 
d
p = 
0.00028** 
c
p = 0.04* 
1вс3 
d
p = 0.014* 
 120 (48-228) 120.5 (63-204) 218 (162.5-313) 
Dischagre 13.82 ± 22.9 12.6 ± 16.1 32.43 ± 47.3 
 6 (3-15) 7 (3-14) 17 (4.5-33.5) 
b
p (Analisys of variance); 
c
p (Kruskal-Wallis test); 
d
p (Mann-Whitney test); *p < 0.05; **p < 
0.01. 
 
Regarding the other two radiographic 
parameters analysed, distribution by extensiveness 
and prevalence of pulmonary changes, comparative 
analysis of the results confirmed the only significant 
difference between the group with CPPE and the 
group with CAP without effusion (p = 0.0001, p = 
0.00005). Diffuse pulmonary changes were detected 
more frequently in the group with CAP without 
effusion compared with the group with CPPE (64.86% 
vs. 27.27%), while the segment distribution was more 
common finding in the group with CPPE (50 % vs. 
stands at 20.27%).  
Unilateral localization of the inflammatory 
process was common finding in the group with CPPE 
compared with the group with CAP without effusion 
(79.55% vs. 44.59%), while patients with CAP without 
effusion were more likely than those with CPPE had 
radiographic finding of both lungs (55.41% vs. 
20:45%) (Table 6). 
 
 
Discussion  
 
Pneumonia can be complicated by the 
development of parapneumonic effusion, which has 
increased morbidity and mortality. Aside from 
inflammation in the lung and pleural space from direct 
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invasion of bacteria and bacteriologic virulence 
features contributing to parapneumonic effusion, 
patient’s factors and comorbidities also contribute to 
the pathophysiology of parapneumonic effusion 
development.  
Table 6: Radiographic characteristics of the three groups of 
patients 
Variable CAP without 
effusion 
N = 148 
UCPPE 
N = 50 
CPPE 
N = 44 
p-value 
 1 2 3  
Type of pulmonary infiltrates n (%) 
Alveolar 
infiltrates 
50 (33.78) 22 (44) 29 (65.91) 
a
p = 0.0012** 
1vs3 p = 0.00019** 
2vs3 p = 0.035* Interstitial 
infiltrate 
22 (14.86) 4 (8) 0 
Mixed (alveo- 
interstitial 
infiltrate) 
76 (51.35) 24 (48) 15 (34.09) 
Distribution according to infiltrate extensiveness n (%) 
Diffuse 96 (64.86) 25 (50) 12 (27.27) 
a
p = 0.0007** 
1vs3 p = 0.0001** 
 
Multilocular 3 (2.03) 1 (2) 2 (4.55) 
Lobar 19 (12.84) 11 (22) 8 (18.18) 
Segmental 30 (20.27) 13 (26) 22 (50) 
Distribution of changes in lung n (%) 
Unilaterally 66 (44.59) 32 (64) 35 (79.55) 
a
p = 0.00008** 
1vs3 p = 0.00005** 
 
Bilaterally 82 (55.41) 18 (36) 9 (20.45) 
a
p (Chi-square test);
 c
p (Kruskal-Wallis test); 
d
p (Mann-Whitney test); *p < 0.05; **p < 0.01. 
 
A recent study [11] analysed 4715 patients 
with CAP and 882 (19%) had pleural effusion, of 
which 261 (30%) had complicated parapneumonic 
effusion or empyema. In this study a multivariable 
analysis, no single baseline patient’s characteristics 
distinguished patients without pleural effusion from 
those with uncomplicated parapneumonic effusion. 
However, five independent baseline characteristics 
could predict the development of complicated 
parapneumonic effusion or empyema: age < 60 years 
old, alcoholism, pleural pain, tachycardia and 
leucocytosis. These investigators and others have 
found a reduced prevalence of clinical manifestation in 
older patients, suggesting a possible age-related 
change in the immune response [11-13]. In our study 
patients with complicated parapneumonic effusion are 
younger compared with patients with CAP without 
effusion and those with UCPPE but there is no 
significant statistical difference regardless of age.  
But when it comes to comorbidities, patients 
with complicated parapneumonic effusion have more 
comorbidities of patients with CAP without effusion 
and patients with UCPPE. As in the previously 
mentioned Falguera’s study, and in Chalmer’s study 
realised in 2011 [10], in our study also alcoholism was 
the most common comorbidities which were noted in 
patients with CPPE, then followed diabetes mellitus. 
In patients with CAP without effusion and patients with 
UCPPE most common accompanied disease in this 
research is chronic heart failure [4, 14]. Having more 
than one comorbidity proved significant in our study in 
the development of CPPE [14].  
In an earlier study as the most common 
comorbidity when it comes to CPPE were reported 
diabetes mellitus, malignancy, and then alcoholism, 
cardiovascular disease, liver cirrhosis and 
immunosuppressive states (HIV infection) [5, 12, 15, 
16]. In Chapman’s study from 2004 [7] and Finish 
study from 2014 [3], it is generally accepted that 
diabetes mellitus increases susceptibility to infection 
and diabetes is typically included in the list for pleural 
infection and empyema. Perhaps the explanation for 
alcoholism, like as a significant risk factor is the 
existence of anaerobic infections in these patients, is 
associated with poor dental hygiene and aspiration. 
CPPE and empyema occur commonly, however, in 
the absence of any identifiable risk factors [7].  
In daily practice, medical doctors first 
encounter with the clinical features of patients. 
Unfortunately, the symptoms of pneumonia involving 
parapneumonic effusion or empyema (i.e fever, 
malaise, cough, dyspnea and pleural chest pain) are 
similar to those of pneumonia without a 
parapneumonic effusion [1, 2, 7]. The symptoms with 
a parapneumonic effusion can be either acute or 
chronic [1, 7, 17]. Anaerobic pulmonary infections 
frequently have an associated pleural effusion and are 
characterised by a more chronic course [1, 2, 11, 17]. 
Weight loss and anaemia are common with anaerobic 
infection [1, 7]. Similarly, if the patients have a 
parapneumonic effusion, the clinical picture is similar 
whether or not the effusion is complicated [1].  
Very high percentage of patients with CPPE 
had dyspnea (88.64%), despite the significantly lower 
percentage of patients with CAP without effusion 
(47.97%), and significantly lower percent patients with 
UCPPE (52%). Pleuritic chest pain (86.36%) was the 
most common symptom and significantly more often 
in a group with CPPE, then to group with UCPPE 
(60%), and group with CAP without effusion (25.68%). 
Weight loss is statistically significantly more frequent 
in patients with CPPE (86.36%) than in patients with 
UCPPE (60%), and patients with pneumonia without 
effusion (51.35%). These results correlate with 
findings from two major studies of Chalmers and 
Falguera that pleural chest pain correlated with other 
factors (clinical, laboratory and microbiological) can 
predict the development of complicated 
parapneumonic effusion or empyema [10, 11]. But, 
the absence of pleural chest pain does not exclude 
pleural infection [18].  
Our results show that significantly different 
duration of disease symptoms before hospitalisation 
(p = 0.0002). This difference was due to a significantly 
longer duration of symptoms in the group with CPPE 
compared with the group with CAP without effusion (p 
= 0.00006). The length of illness > 5 days is more 
common in patients with CPPE, and we found the 
average length of illness of 10 days (5-13.5 days) in 
our patients with CPPE [11]. The length of 
hospitalisation significantly differed among the three 
groups of patients (p < 0.0001). The average time of 
hospital days shows that half of the patients with 
CPPE were in the hospital more than 21 days, half of 
the patients with CAP without effusion were 
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hospitalised more than 12 days, 50 % of patients with 
UCPPE more than 15 days. Significantly different 
length of hospitalisation was reported in several 
studies [1, 2, 7, 10, 11, 17, 18]. Тhis is due to 
shortcomings in the management of patients with 
pneumonia and UCPPE. Early antibiotic treatment will 
prevent the development of UCPPE and progression 
to CPPE and empyema. In that case, effusion is 
associated with antimicrobial treatment failure [1-3], 
prolonged systematic sepsis, increased the length of 
hospital stay [2], higher financial costs [2] greater 
morbidity from invasive procedures [17, 18] and 
greater mortality [1-3, 7, 10, 11].  
We found and that duration of elevated 
temperature before and after hospitalisation in 
patients with CPPE significantly different from the 
length and duration of the temperature in the 
remaining two groups of patients. Average value of 
temperature during hospital treatment in patients with 
CPPE was 39
0
C (38.25-39.8
0
C) in patients with 
UCPPE was 38.4
0
C (37.5-39.6
0
C) and the lowest 
values were noted in the patient with CAP without 
effusion 38.3
0
C (37.4-39.2
0
C). This suggests that the 
temperature as a clinical marker of inflammation is 
higher and longer lasting in patients with complicated 
effusion. A temperature that persists in patients with 
pneumonia suggests that the inflammatory process 
takes the adverse course and complicating [19-21]. 
We decided to see if the standard markers of 
inflammation, like ERS and WBC, which are widely 
used in everyday practice, may indicate what course 
shall take and whether pneumonia complicated by the 
development of effusion. WBC has an important role 
in the inflammatory response to infection and the 
release of pro- inflammatory cytokines [21]. In our 
study, there were significantly higher values of WBC 
in patients with effusion especially in patients with 
CPPE like in study of Kruger and associates [21]. We 
found that higher value of WBC than 20 x 10
9
 at 
admission at the clinic are meet in 25% of patients 
with CPPE because the patients with CPPE have a 
more severe clinical picture unlike patients with CAP 
without effusion and patients with UCPPE [1, 8].  
Patients with CPPE had average ERS in the 
first hour of 74.77 ± 27.3 mm/h and is significantly 
higher than the average value in the group with 
pneumonia without effusion (56.35 ± 28.6 mm/h), and 
the average value of the group with UCPPE (60.02 ± 
27.7 mm/h). Our result is the same as in growing 
number of studies, but just like WBC and ESR is a 
nonspecific marker that indicates not only the severity 
of the infection but increases in other types of 
inflammation [22, 23]. ERS is helpful in monitoring 
chronic inflammatory condition but does not benefit at 
monitoring responses to therapy in acute inflammatory 
conditions, such as acute infections [22].  
Unlike the previous two markers CRP is more 
beneficial in acute infections Our results show that the 
mean values of CRP (231.79 ± 112.2 mg/L) were 
significantly higher in the group with CPPE compared 
with the group with UCPPE (163.8 ± 147.9 mg/L) (p = 
0.000065), and especially compared with the group 
with CAP without effusion (139.48 ± 105.7 mg/L) (p = 
0.000004). Chalmers et al have reported an 
association of a low CRP level of >= 100 mg/l at the 
time of hospital admission with a reduced risk of 30- 
day mortality, need for mechanical ventilation and/or 
inotropic support, and complicated pneumonia [24]. 
Similar results are and Mira in their study published 
2008 in a group of patients hospitalised in intensive 
care unit [25].  
Eisenhut’s study from 2008 suggests that a 
persistently elevated or rising CRP level in a patients 
on the ICU should, therefore, alert the clinician not 
only to a potentially poor prognosis but also prompt a 
reassessment of the patients with a chest X- ray and 
chest ultrasound for the presence of an empyema that 
may require surgical evacuation [26]. Alveolar 
infiltrates with segment distribution and unilateral 
distribution of changes in the lung are associated with 
complicated parapneumonic effusion in the conducted 
study. Unlike them in patients with pneumonia usually 
meet mixed (also- interstitial infiltrate), according to 
infiltrate extensiveness diffuse distribution, and 
bilaterally distribution of changes in the lung.  
If you know that about 200 ml of pleural fluid 
is detectable on PA chest radiography whereas only 
50 ml fluid is detectable on a lateral film [8]. Chest 
radiography with lateral decubitus film in everyday 
practice is not realised. Very often there is a pleural 
effusion that classical chest radiography not 
visualises.  
Ultrasound is more accurate and more 
sensitive for estimable pleural fluid volume and aids 
thoracocentesis [8, 27, 28]. Ultrasound is also useful 
in showing separation and echogenicity (correlating 
with an exudate) and differentiates between the 
pleural fluid and thickening [8, 27, 28]. It is portable 
and position flexible [8]. So when we see segmental 
or lobar pneumonia without recording the effusion is 
necessary to consider and such a complication and 
make lung ultrasound. 
We can summarise that if we have a patient 
aged 60 years with a fever that lasts longer, elevated 
leukocyte, persisting elevated CRP and radiographic 
findings of segmental or lobar pneumonia should 
suspect to a parapneumonic effusion as a possible 
complication, especially CPPE.  
In conclusion, perhaps our study will help to 
clarify some contradictions that are associated with 
pneumonia and development of parapneumonic 
effusions, especially CPPE. But, proper analysis of 
clinical, laboratory and radiographic features, 
together, of patients with CAP, UCPPE and CPPE to 
prevent mismanagement of these patients, will reduce 
morbidity and mortality and help to define new 
diagnostic and therapeutic approaches. 
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